{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:00:16Z","timestamp":1761897616441},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,5,1]]},"DOI":"10.2169\/internalmedicine.7768-21","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T22:13:07Z","timestamp":1633990387000},"page":"1337-1343","source":"Crossref","is-referenced-by-count":6,"title":["Safety Profile of Ixazomib in Patients with Relapsed\/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance"],"prefix":"10.2169","volume":"61","author":[{"given":"Yoshihide","family":"Kakimoto","sequence":"first","affiliation":[{"name":"Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Hiraizumi","sequence":"additional","affiliation":[{"name":"Pharmacovigilance, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Biostatistics, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Japan"},{"name":"Niigata Kenshin Plaza, General Incorporated Foundation, Health Medicine Prevention Association, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Cancer Information Service, National Cancer Center, Japan. Cancer Registry and Statistics. [Internet]. Ministry of Health, Labour and Welfare, National Cancer Registry. 2016-2017 [cited 2021 Jun]. Available from: https:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/ (in Japanese)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ozaki S, Handa H, Saitoh T, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5: e349, 2015.","DOI":"10.1038\/bcj.2015.79"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"4","unstructured":"4. Ozaki S. Treatment algorithms for multiple myeloma in Japan. Rinsho Ketsueki (Jpn J Clin Hematol) 58: 1014-1023, 2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Iida S, Ishida T, Murakami H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol 109: 509-538, 2019.","DOI":"10.1007\/s12185-019-02636-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374: 1621-1634, 2016.","DOI":"10.1056\/NEJMoa1516282"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mehta J, Cavo M, Singhal S. How I treat elderly patients with myeloma. Blood 116: 2215-2223, 2010.","DOI":"10.1182\/blood-2009-10-163329"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106: 3777-3784, 2005.","DOI":"10.1182\/blood-2005-03-1173"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol 178: 571-582, 2017.","DOI":"10.1111\/bjh.14733"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clinical pharmacology of ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet 58: 431-449, 2019.","DOI":"10.1007\/s40262-018-0702-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 42: 157-176, ix-x, 2016.","DOI":"10.1016\/j.rdc.2015.08.004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100: 107-113, 2015.","DOI":"10.3324\/haematol.2014.107714"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8: 46593-46600, 2017.","DOI":"10.18632\/oncotarget.16235"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7768-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:12:25Z","timestamp":1715231545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/9\/61_7768-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7768-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]},"article-number":"7768-21"}}